Loading
Life sciences · Journal article
Explore Medical Science and Global Health · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Since its inception, chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in relapsed and refractory hematologic malignancies. However, issues such as low response rates in solid tumors, lengthy and costly autologous product preparation, and insufficient long-term safety data have consistently limited its broader clinical application. The maturation of CRISPR/Cas9 gene editing technology has provided new tools to address these bottlenecks—by simultaneously modifying multiple targets in the T-cell genome, researchers can construct off-the-shelf allogeneic CAR-T products, knock out immune checkpoints to enhance antitumor activity, integrate safety switches to control toxicity, and even expand indications to autoimmune diseases. This article focuses on the technical approaches for optimizing CAR-T cells through gene editing. It reviews the current state of research on three strategies—the construction of universal products, enhancement of therapeutic efficacy, and improvement of safety—and, drawing on the latest clinical data from the fields of hematologic malignancies, solid tumors, and autoimmune diseases, discusses unresolved issues such as off-target effects, T-cell exhaustion, and manufacturing processes. The article also provides an outlook on cutting-edge directions, including in vivo CAR-T cells and iPSC-derived cells.